Hypercholesterolemia is one of the principal promoters of the atherosclerotic plaque genesis (Steinberg, ), representing a relevant cardiovascular (CV) risk factor (Mozaffarian et al., ). Therefore, a goal of primary and secondary prevention of CV diseases is the reduction of low‐density lipoprotein (LDL) cholesterol levels (National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III], ). In this context, the use of statins as lipid‐lowering drugs has been, until now, a key step in reducing the CV risk (Naci et al., ; Taylor, Huffman, & Ebrahim, ); however, a new class of lipid‐lowering drugs that significantly reduce the levels of LDL cholesterol has recently emerged: the inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) (Giugliano & Sabatine, ; Gouni‐Berthold & Berthold, ; Sahebkar, Chew, & Watts, ; Sahebkar & Watts, ). PCSK9 is a protein that interacts with the LDL receptor (LDLR) favoring early degradation and preventing recycling. Monoclonal antibodies against PCSK9 increase the hepatic gene expression of LDLR, resulting in a pronounced cholesterol‐lowering effect caused by the LDL internalization processes.However, despite the enthusiasm generated by the efficacy of such drugs in lowering LDL cholesterol (Canevari &
Journal of Neuroscience Research – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud